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Bone marrow (BM) fibrosis is a feature of severe hy-
perparathyroidism. Consistent with this observation,
mice expressing constitutively active parathyroid
hormone (PTH)/PTH-related peptide receptors (PPR)
in osteoblasts (PPR*Tg) display BM fibrosis. To obtain
insight into the nature of BM fibrosis in such a model,
a double-mutant mouse expressing constitutively ac-
tive PPR and green fluorescent protein (GFP) under
the control of the type I collagen promoter (PPR*Tg/
GFP) was generated. Confocal microscopy and flow
cytometry revealed the presence of a cell population
expressing GFP (GFP) that was also positive for the
hematopoietic marker CD45 in the BM of both
PPR*Tg/GFP and control animals. This cell population
was expanded in PPR*Tg/GFP. The existence of cells
expressing both type I collagen and CD45 in the adult
BM was confirmed by IHC and fluorescence-activated
cell sorting. An analysis of total RNA extracted from
sorted GFPCD45 cells showed that these cells pro-
duced type I collagen and PTH/PTH-related peptide re-
ceptor and receptor activator for NF-B mRNAs, furthersupporting their features of being both mesenchymal
and hematopoietic lineages. Similar cells, known as fi-
brocytes, are also present in pathological fibroses. Our
findings, thus, indicate that the BM is a permissive mi-
croenvironment for the differentiation of fibrocyte-like
cells and raise the possibility that these cells could con-
tribute to the pathogenesis of BM fibrosis. (Am J Pathol
2012, 180:811–818; DOI: 10.1016/j.ajpath.2011.10.028)
The bone marrow (BM) is a complex microenvironment
composed of both hematopoietic and mesenchymal
cells. Hematopoietic cells, including bone-resorbing os-
teoclasts, derive from self-renewing hematopoietic stem
cells (HSCs) and constitute most of the adult BM cellu-
larity. The mesenchymal population, comprising osteo-
blasts (ie, the cells making bone) and adipocytes, is
thought to originate from mesenchymal stem cells
(MSCs).1 Recent studies2–5 have challenged the simple
dichotomy hematopoietic versus mesenchymal by rais-
ing the intriguing possibility that cells of hematopoietic
origin could differentiate into mesenchymal lineages.
The BM stroma consists of a heterogeneous popula-
tion that provides support to hematopoietic cells and
contains cells that can differentiate into various mesen-
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AJP February 2012, Vol. 180, No. 2chymal cell lineages. Marrow fibrosis is a pathological
condition characterized by expansion of the BM stroma,
with consequent abnormal accumulation in the BM of
fibroblastoid cells and collagen fibers. It can be idio-
pathic, although in humans it is often a feature of a variety
of malignancies of the hematopoietic system, such as
myelofibrosis,6,7 and of nonmalignant pathological con-
ditions, such as severe primary and secondary hyper-
parathyroidism8–10 and fibrous dysplasia.11 Consistent
with these findings, transgenic mice expressing constitu-
tively active parathyroid hormone (PTH)/PTH-related pep-
tide receptors in osteoblasts (PPR*Tg) show a considerable
accumulation of fibroblastoid cells in their BM.12
Marrow fibrosis could be a disease of MSCs.13 In this
regard, the number of CD146CD45 skeletal stem
cells14 is augmented in the BM of patients with myelofi-
brosis, which suggests that MSCs/mesenchymal progen-
itors could be involved in the pathogenesis of BM fibro-
sis.15 Interestingly, a heterogeneous group of cells of BM
origin, expressing both hematopoietic and mesenchymal
markers, has recently been identified in the circulation
and at sites of pathological fibroses.16–18 To this end, no
evidence that such cells are, indeed, present in the BM in
vivo has been reported.
To gain more insights into the complexity of the BM
stroma in a model of BM fibrosis, we, thus, studied
whether the stroma expansion observed in the BM of
PPR*Tg mice was concomitant to a modulation of the
pool of immature mesenchymal cells or whether it shared
features of cells involved in pathological fibroses.
Materials and Methods
Mice
Transgenic mice expressing constitutively active PTH/
PTH-related peptide receptors (PPR*) under the control
of the 2.3-kb fragment of the mouse a1 (I) collagen gene
promoter (PPR*Tg) and transgenic mice expressing
green fluorescent protein (GFP) under the control of the
2.3-kb fragment rat a1 (I) collagen gene promoter [wild
type (WT)/GFP] have been previously described.19 Hem-
izygous WT/GFP mice were crossed with hemizygous
PPR*Tg mice, and double-hemizygous mutant mice were
generated (PPR*Tg/GFP). C57BL/6 mice were obtained
from Animal Resources Center, Perth, WA, Australia. All
studies were approved by an animal care committee of
each institution.
Preparation of BM Cells for Flow Cytometry
Analysis or Cell Sorting
Tibiae, femurs, and iliac crests were isolated from either
6- to 8-week-old WT and PPR*Tg mice or 6- to 8-week-old
WT/GFP and PPR*Tg/GFP mice. After scraping the peri-
osteum with scalpels, bone specimens were digested
with a solution containing collagenase 1 and collagenase
2 (Worthington, Lakewood, NJ), for 15 minutes at 37°C, to
completely eliminate the periosteum. Epiphyses were de-
tached, and specimens were crushed in PBS using mor-tal and pestle. Cells were then flushed through cell strain-
ers (BD/Falcon, Franklin Lakes, NJ), layered over Ficoll-
Paque PLUS (GE Healthcare, Upsala, Sweden), and
centrifuged for 10 minutes at 4°C. Low-density cell frac-
tions were collected and resuspended in one times
PBS–2% fetal bovine serum at a concentration of 1  107
cells/mL. Thereafter, collected cells were stained and
analyzed by flow cytometry using an LSRII, an FACSCali-
bur, or an LSRFortessa analyzer (BD/Falcon for all), or
sorted using an FACS Aria cell sorter (BD).
PTH Administration and Preparation of
Endosteal-Enriched BM Cells for Flow
Cytometry Analysis
C57BL6 WT mice, aged 6 to 8 weeks, were injected s.c.
with either PBS or PTH (1–34) at 80 g/kg per day.
Muscular tissue was removed, and BM was flushed with
10 mL of HBSS media, pH 7.4, supplemented with 2%
fetal calf serum (FCS). Erythrocytes were lysed by hypo-
tonic shock, and flushed cells were then spun down and
finally resuspended in HBSS/FCS (fraction 1). Flushed
bones were cut into small chips, placed in 50-mL conical
tubes, and rinsed in PBS to eliminate loosely attached
cells. Bone chips were then suspended in 2.5 mL of PBS,
containing 2 mg/mL collagenase A and 2 mg/mL hyal-
uronidase, and incubated at 37°C, with intermittent vor-
tex mixing. After 25 minutes, supernatant was re-
moved, and bone chips were then subjected to a
second digestion with 2 mL of 2 mg/mL collagenase A
and 2 mg/mL hyaluronidase dissolved in 0.25% tryp-
sin-EDTA, for 45 minutes at 37°C, with intermittent vor-
tex mixing. After incubation, supernatant was removed
and trypsin was inactivated with 15% serum. Both di-
gested fractions were combined, washed several times
in HBSS-FCS, and filtered through a 70-mm cup
strainer. This fraction (fraction 2) was enriched for cells
of the endosteal compartment.
Flow Cytometry
BM cells, isolated from WT or PPR*Tg mice, were incu-
bated with CD31–activated protein C (APC), CD45-APC,
and stem cell antigen 1 (ScaI)–phosphatidylethano-
lamine (PE)–Cy5.5 antibodies (eBioscience, San Diego,
CA) on ice for 30 minutes. Cells were then washed with
PBS–2% fetal bovine serum and analyzed on an LSRII or
an FACSCalibur analyzer (BD for both). BM cells isolated
from WT/GFP mice, with or without PTH treatment, or
PPR*Tg/GFP mice were incubated with CD45-PE or
CD45-APC and CD11b-APC antibodies (eBioscience)
and analyzed as previously described.
Analysis of collagen 1–positive cells in lineage-nega-
tive BM cells of WT mice was performed by staining BM
cells isolated from C57BL/6 WT mice with a cocktail of
PE-conjugated rat anti-mouse antibodies against Ter119,
CD4, CD8, B220, and Gr-1 for lineage depletion. Analysis
was also performed with CD45.2–Alexa Fluor 700,
CD11b–fluorescein isothiocyanate, ScaI-PE-Cy7, c-Kit-
APC-eFluor780, and F4/80-eFluor450 antibodies (all from
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anti-mouse type 1 collagen antibody (Rockland, Gilberts-
ville, PA) or a biotinylated rabbit IgG-(Fc) isotype control
( Diagnostic International Inc., San Antonio, TX) on ice
for 30 minutes. Cells were then washed, incubated with
streptavidin PerCP-Cy5.5 antibody (eBioscience) on ice
for 30 minutes, and analyzed as previously described.
The cell populations shown were gated on lineage-neg-
ative cells from the BM.
RT-PCR Data
RNA was isolated from sorted cells (up to 1  105 cells)
by using an RNeasy kit (Qiagen, Hilden, Germany). First-
strand cDNA was synthesized using the QuantiTect Re-
verse Transcription kit (Qiagen). The RT-PCR was per-
formed in a 25-L reaction mixture of Illustra PureTaq
Read-to-go beads (GE Healthcare) containing 1 L of
cDNA samples. The PCR conditions were as follows:
95°C for 1 minute, 58°C for 45 seconds, and 72°C for 1
minute, for a total of 35 cycles. The primer sequences are
as follows: type 1 collagen, 5=-TGTGTGCGATGACGTG-
CAAT-3= (forward) and 5=-GGGTCCCTCGACTCCT-
ACA-3= (reverse); GFP, 5=-CAAGATCCGCCACAACATC-
GAG-3= (forward) and 5=-ATGTGATCGCGCTTCTC-
GTTGGGG-3= (reverse); receptor activator for NF-B
(RANK), 5=-GGACGGTGTTGCAGCAGAT-3= (forward)
and 5=-CGAGTCTGAGTTCCAGTG-GTA-3= (reverse);
PTH1R, 5=-GTGGGACAACATCGTTTGCTG-3= (forward) and
5=-CGGTCAAATACCTCCCG-TTC-3= (reverse); -actin, 5=-
GGCTGTATTCCCCTCCATCG-3= (forward) and 5=-CCAGT-
TGGTAACAATG-CCATGT-3= (reverse); and PPR*Tg, 5=-
CACCTGCCCTGCTACAGGAAGAG-3= (forward) and 5=-
TTCCACCACTG-CCTCCCATTCATC-3= (reverse).
IHC on Undecalcified Cryosections
Femora isolated from 6- to 8-week-old PPR*Tg/GFP mice
were excised, snap frozen in n-hexane/dry ice (approxi-
mately 70°C), and embedded in super cryosection em-
bedding medium (Section-Lab, Hiroshima, Japan). Non-
decalcified longitudinal sections of femurs were cut using
a tungsten blade and a tape transfer system (CryofilmIIC;
Section-Lab). Nondecalcified sections were adhered on
the adhesive side of cryofilms and analyzed as attached
throughout. Sections on cryofilms were rapidly dehy-
drated in 100% ethanol for 1 minute, air dried completely,
and kept at 20°C until use. Slides were rinsed in 0.1%
Tween 20 in Tris-buffered saline three times, blocked with
2% BSA–0.1% Tween 20 in Tris-buffered saline for 30
minutes at room temperature, and incubated with primary
antibodies diluted in blocking solution overnight at 4°C.
Secondary antibodies were diluted in blocking solution
and incubated for 3 hours at 4°C, followed by nuclear
staining with TO-PRO-3 (1:1000; Invitrogen, Carlsbad,
CA) for 15 minutes at room temperature. The following
antibodies were used: anti-GFP polyclonal (1:200; Ab-
cam, Cambridge, MA), anti-CD45 monoclonal (1:200;
Abcam), anti-collagen 1 polyclonal (1:200; Abcam), Al-
exa 488–conjugated goat anti-rabbit IgG (1:400; Ab-
cam), and Alexa 546–conjugated goat anti-rat IgG (1:400; Abcam). A confocal laser microscope (LSM510
Pascal; Carl Zeiss, Oberkochen, Germany) was used for
signal visualization, with an excitation wavelength of 488/
520/610 nm and band-pass filters of 515/550/630 nm,
respectively.
Detection of GFP Signaling and TRAP Staining
on Decalcified Cryosections
Tibias isolated from WT/GFP or PPR*Tg/GFP mice were
fixed in 4% paraformaldehyde for 48 hours at 4°C. Spec-
imens were decalcified in 20% EDTA solution at 4°C for 7
days, and the EDTA solution was changed daily. Decal-
cified bones were then soaked in 30% sucrose/one times
PBS for 24 hours, and embedded in Optimal Cutting
Temperature compound (Sakura, Tokyo, Japan). Sec-
tions (10 m thick) were air dried, rehydrated, and
mounted. Pictures were then taken for documentation of
GFP expression. In selected cases, sections were im-
mersed in water to wash out the mounting media, and
tartrate-resistant acid phosphatase (TRAP) staining was
performed using an acid phosphatase detection kit (Sig-
ma-Aldrich Corp, St Louis, MO).
IHC and in Situ Hybridization on Paraffin
Sections
The tibias of WT and PPR*Tg mice were fixed in 4%
paraformaldehyde at 4°C for 48 hours. After decalcifica-
tion with 20% EDTA at 4°C for 7 days, paraffin blocks
were prepared by standard procedures. The sections
were deparaffinized, and antigen retrieval was performed
using proteinase K (20 mg/mL; Roche, Indianapolis, IN),
followed by 10-minute treatment with 3% H2O2 to block
endogenous peroxidase. The presence of immature pro-
genitors was detected using anti-mouse ScaI Ab (BD) at
a dilution of 1:500 for 1 hour at room temperature and the
Tyramide Signal Amplification biotin system (Perkin-El-
mer, Waltham, MA), according to the manufacturer’s pro-
tocol. In situ hybridization analyses were performed as
previously described12 using 35S-labeled riboprobes on
paraffin sections of bone specimens prepared, as previ-
ously described.
Results
Marrow Fibrosis in PPR*Tg Mice Is Formed by
Type I Collagen–Producing Cells but Not by
Terminally Differentiated Osteoblasts
A considerable expansion of a fibroblastoid population or
marrow fibrosis was observed in the BM of 2-week-old
PPR*Tg mice, particularly in their metaphyseal regions,
and persisted until at least the age of 16 weeks (Figure
1A).12 In situ hybridization analysis showed that these
cells were heterogeneously expressing type I collagen
mRNA (Col I), whereas osteocalcin mRNA, which is a
classical marker of terminally differentiated osteoblasts,
nd PPR
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bone surfaces but not in the marrow stroma (Figure 1B).
To gain more insights into the nature of the marrow
fibrosis observed in PPR*Tg mice, we took advantage of
a transgenic mouse line that expresses GFP in mature
osteoblasts under the control of a 2.3-kb fragment of the
rat a1 (I) collagen gene promoter (WT/GFP),19 which is
similar to the promoter fragment driving expression of
PPR* in PPR*Tg mice. PPR*Tg and WT/GFP mice were
crossed to generate PPR*Tg/GFP double-hemizygous
mice. Histological analysis of decalcified frozen sections
of adult tibias isolated from PPR*Tg/GFP mice revealed
that, as previously reported,19 osteoblasts closely adja-
cent to bone surfaces expressed considerable amounts
of GFP (Figure 1C). Conversely, most stromal cells did
not express GFP to a detectable level, although a few
fibroblastoid cells were positive for this fluorochrome
(Figure 1C). In contrast to findings in transgenic mice
expressing GFP under the control of the 3.6-kb fragment
of the a1 (I) collagen gene promoter,20 no expression of
GFP was detectable in TRAP-positive multinucleated os-
teoclasts (Figure 1C).
Taken together, these data indicate that most fibro-
GFPGFP TRAP/HE
A WT PPR*Tg
H&E H&E
C PPR*Tg/GFP
TRAP/HE
BMBM
GFP
Figure 1. A: Expansion of stromal cells in trabecular bone areas of PPR*T
16-week-old WT and PPR*Tg mice is shown. Original magnification, 20
hybridized with specific riboprobes for detection of type I collagen (Col I) an
dark fields are shown. Original magnification, 20. Arrows indicate that s
isolated from PPR*Tg/GFP mice. Decalcified frozen section of tibias isolated
GFP (left panels). Sections were then stained for TRAP and H&E (right p
Original magnification: 20 (top panels); 40 (bottom panels). Areas su
osteoblasts and osteocytes are GFP. Yellow arrowheads indicate TRAP-
staining for ScaI. Histological sections of tibias isolated from WT and PPR
diaminobenzidine. Images of trabecular bone areas are shown. In both genot
Osteoblasts on bone surfaces (arrows) were negative for ScaI in both WT a
areas). Original magnification, 40.blastoid cells present in the marrow stroma of PPR*Tgmice are not terminally differentiated osteoblasts, al-
though they produce type I collagen, which is suggestive
of a mesenchymal identity of these cells.
Marrow Fibrosis in PPR*Tg Mice Is Not
Contributed by Immature Progenitor Cells
We next determined whether the expansion of fibroblas-
toid cells observed in the BM of PPR*Tg mice was the
result of an increase of immature progenitors of the mes-
enchymal lineage. Several lines of evidence suggest that
ScaI is expressed in mesenchymal progenitors.21–23 We,
thus, performed immunohistochemical (IHC) staining for
ScaI on histological sections of bone specimens isolated
from WT and PPR*Tg mice. As expected, terminally differ-
entiated osteoblasts in either genotype did not express de-
tectable levels of ScaI (Figure 1D). Most fibroblastoid cells
in the BM were also negative for ScaI (Figure 1D). Interest-
ingly, an intense ScaI-positive staining was observed in and
adjacent to the wall of sinusoidal blood vessels (Figure 1).
A BM population positive for ScaI and negative for the
pan-leukocyte marker CD45 and for the endothelial cell
WT PPR*Tg
ca I Sca I
PPR*Tg PPR*Tg
ol I OCN
ol I OCN
H&E staining of paraffin sections of decalcified mouse tibias isolated from
calcified paraffin sections of tibias isolated from adult PPR*Tg mice were
alcin (OCN) mRNAs, by in situ hybridization. Bright fields (top panels) and
ells express Col1 but not OCN. C: Histological analysis of bone specimens
-week-old PPR*Tg/GFP mice were first analyzed to identify cells expressing
Bottom panels: Magnified images of the boxed areas in the top panels.
d by dotted lines in the bottom panels indicate bone matrix. Bone-lining
osteoclasts. White arrowheads indicate GFP stromal cells. D: Immuno-
e were incubated with ScaI antibody; antibody binding was detected by
lls in the wall of blood vessels (double arrowheads) were positive for ScaI.
*Tg mice. Most stromal cells in PPR*Tg mice were negative for ScaI (circledD
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population was, indeed, present in the BM of either WT or
PPR*Tg mice by flow cytometry analysis performed on
crushing of adult bone specimens (Figure 2A); how-
ever, no significant difference in the percentage of
ScaICD45CD31 cells per total BM cells could be
detected between PPR*Tg and WT mice (Figure 2B). In
agreement with the observation that ScaICD45CD31
population is enriched in immature progenitors,22 flow
cytometry analysis of BM cells isolated from either WT/
GFP mice or PPR*Tg/GFP mice indicated that the
ScaICD45CD31 population does not express detect-
able levels of GFP (data not shown).
Taken together, our data suggest that the fibroblastoid
population forming the marrow fibrosis in PPR*Tg mice is
not a population of immaturemesenchymal progenitor cells.
A Population of Cells Expressing Both
Hematopoietic and Mesenchymal Markers Is
Present in the Normal Adult BM and Is
Significantly Augmented in the PPR*Tg
To distinguish hematopoietic and nonhematopoietic cells
in the BM of PPR*Tg mice, we performed confocal mi-
croscopy analysis of frozen bone sections isolated from
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Figure 2. Flow cytometry analysis of BM cells isolated from WT and PPR*Tg
mice. BM cells were collected as described in Materials and Methods, and
were then incubated with ScaI-PE-Cy5.5, CD45-APC, and CD31-APC antibod-
ies. A: Representative analysis of BM cells isolated from WT and PPR*Tg
mice. B: A summary of the percentage of ScaICD45CD31 cells in WT
(n  6) and PPR*Tg (n  6) mice from two independent sets of experiments
is shown. Each symbol represents a separate mouse. The same symbol
indicates the data came from the same experiment within the two replicate
experiments. P  0.69.PPR*Tg/GFP mice by staining with the pan-leukocytemarker CD45. No CD45 signal was observed in speci-
mens stained with an isotype control antibody or in the
absence of a primary antibody (data not shown). As
expected, GFP bone-lining osteoblasts were negative
for CD45 (Figure 3A). However, surprisingly, we identified
fibroblastoid cells that were positive for both GFP and
CD45 (GFPCD45) (Figure 3A). Similar findings were
obtained when confocal microscopy analysis was per-
formed to detect native type I collagen and CD45 pro-
teins on equivalent specimens obtained from PPR*Tg
mice (Figure 3B).
To further characterize the GFPCD45 cells identi-
fied in the BM of PPR*Tg/GFP mice by confocal micros-
copy, we then performed flow cytometry analysis of BM
cells isolated from either WT/GFP or PPR*Tg/GFP mice,
on crushing of the long bones. Notably, we preferred to
crush, rather than to flush, the specimens of interest
because in previous pilot experiments we had not been
μ
μ
PPR*Tg/GFP
PPR*Tg
A
B
Figure 3. A: Confocal microscopy image of a frozen section of a tibia
isolated from PPR*Tg/GFP mice. Tibias of 6-week-old mice were dissected
and processed as described in Materials and Methods. Sections were stained
with anti-GFP polyclonal, anti-CD45 monoclonal, Alexa 488–conjugated
goat anti-rabbit IgG and Alexa 546–conjugated goat anti-rat IgG. TO-PRO-3
was used for nuclear staining. The arrows indicate the presence of
GFPCD45 cells. B: A representative frozen section of a tibia of a PPR*Tg
mouse was incubated with anti-Col I polyclonal, anti-CD45 monoclonal,
Alexa 488–conjugated anti-rabbit IgG and Alexa 546–conjugated anti-rat
IgG. TO-PRO-3 was used for nuclear staining. Arrows indicate the presence
of CD45Col I cells.
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PPR*Tg by flushing, which was likely the result of the
complex trabecular architecture of the mutant mice (data
not shown). To enhance the specificity of our findings, all
duplex events were carefully gated out (data not shown).
Flow cytometry analysis confirmed the presence of
GFPCD45 cells in the BM of both mutant (Figure 4B)
and control (Figure 4A) mice. When isotype control anti-
body was used, no CD45 events could be identified
within the GFP population (data not shown). The
GFPCD45 cell population was significantly expanded in
the BM of PPR*Tg/GFP mice (Figure 4, A–C). Interestingly,
most GFPCD45 cells isolated from either WT/GFP or
PPR*Tg/GFP mice expressed CD11b (Figure 4, A and B).
RT-PCR analysis of total RNA extracted from
GFPCD45 cells, isolated from WT/GFP mice and
sorted twice to eliminate any potential contamination with
other cell types, indicated that these cells expressed
both Col I and GFP mRNAs (Figure 4D). Moreover, native
PPR, which is expressed in MSCs and osteoblasts,24,25
and RANK, which is present in osteoclast lineage cells
and in dendritic cells,26 were also detectable in
GFPCD45 cells by RT-PCR, confirming that these cells
had mixed features of both mesenchymal and hemato-
poietic lineages (Figure 4D). Similar results were ob-
tained in GFPCD45 cells isolated from PPR*Tg/GFP
mice (data not shown). Not surprisingly, these cells also
expressed PPR* transgene mRNA, which, like GFP trans-
gene, is driven by a similar 2.3-kb fragment of the a1 (I)
collagen gene promoter (data not shown). A scarce num-
ber of GFPCD45 cells were also identified by flow cytom-
etry in the BM of either WT/GFP or PPR*Tg/GFPmice, which
were likely to be mature osteoblasts (Figure 4, A and B).
Consistent with this conclusion, GFPCD45 cells did not
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2
1express RANK, as shown by RT-PCR (Figure 4D).We then determined whether CD45 cells express na-
tive type 1 collagen. For this purpose, we stained BM
cells with a cocktail of lineage (Ter119, CD4, CD8, B220,
and Gr-1) antibodies, together with CD45.2, CD11b,
ScaI, c-Kit, and type 1 collagen antibodies, and could
detect a distinct Col1 population in lineage-negative
CD45CD11b cells (Figure 4E). When isotype control
antibody was used, no Col1 events could be identified
within the CD45CD11b population (Figure 4E). Nota-
bly, the Col1CD45CD11b population could be further
divided into two subpopulations, based on the expres-
sion of F4/80 (Figure 4F). Staining the cells for ScaI and
c-Kit at the same time revealed that most of the
CD45CD11b cells were negative for both c-Kit and ScaI
and that the Col1F4/80 and Col1F4/80 cell popula-
tions were predominantly in this HSC-devoid population
(see Supplemental Figure S1 at http://ajp.amjpathol.org).
Taken together, our data indicate that the adult murine BM
contains a novel cell population that displays mixed fea-
tures of mesenchymal and hematopoietic cells; this popu-
lation is significantly expanded in PPR*Tg mice.
PTH Administration Expands the Population of
GFPCD45 in the BM Endosteal Fraction of
WT/GFP Mice
Based on the previous findings, we reasoned that expan-
sion of the GFPCD45 population observed in GFP/
PPR*Tg mice was the result of increased PTH signaling.
To pharmacologically test this possibility, WT/GFP mice
were treated with daily s.c. injections of PTH (1–34) at 80
g/kg or PBS for 28 days. After treatment, mice were
sacrificed and BM cells were isolated from long bones in
a two-step process that included the mechanical flushing
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Figure 4. A–C: Identification and characterization
of GFPCD45 cells in WT and PPR*Tg mice. BM
cells were isolated as described in Materials and
Methods from WT/GFP (A) and PPR*Tg/GFP (B)
mice, and analyzed for the expression of GFP,
CD45, and CD11b. Note the expansion of the
GFPCD45 cell population in PPR*Tg (B, left
panel) compared with WT (A, left panel) mice. A
and B, right panels: Most of the GFPCD45
cells are positive for CD11b. C: Comparison of
percentage of GFPCD45 cells per total BM cells
between WT/GFP (n  4) and PPR*Tg/GFP (n 
5) mice. The results of four independent experi-
ments were summed, and the average values are
shown. A Student’s t-test was performed to vali-
date the significance of difference. P  0.01. D:
GFPCD45 cells, GFPCD45CD11bcells, and
GFPCD45CD11b cells were sorted from the
BM of WT/GFP mice, and total RNA was collected.
RT-PCR was performed for -actin (154 bp), Col I
(133 bp), GFP (159 bp), PPR (225 bp), and RANK
(243 bp) (product size is in parentheses). The MspI
digest of pBR322 DNA was used as mol. wt. stan-
dards. E and F:Detection of CD45CD11b Col1
F4/80 and CD45CD11b Col1 F4/80 cells in
the BM of WT mice. CD45CD11b cells in lin-
eage-negative gated BM are shown (left panels).
These can be further subdivided based on their
expression of F4/80 and Col 1 (F). An isotype
control for Col 1 is shown in E.GFP(+)C
GFP(+)C
GFP(+)C
l1 GF
3 1 2of the BM (fraction 1), followed by digestion of the flushed
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ure 5, we observed an increase in the number of
GFPCD45 cells in fraction 2 collected from PTH-
treated mice compared with control. However, this in-
crease did not reach statistical significance. No differ-
ences were observed between PTH- and vehicle-treated
specimens in fraction 1 (data not shown).
Discussion
In recent years, we have generated a mouse model of
marrow fibrosis by expressing a constitutively active re-
ceptor for PTH in osteoblasts (PPR*Tg).12 In the current
study, analysis of PPR*Tg mouse, a model of BM fibrosis,
has led us to the discovery of a novel BM cell population
constituted by cells that express both mesenchymal and
hematopoietic markers. This novel population, which we
have also successfully identified in normal mice, is sig-
nificantly expanded in PPR*Tg mice.
Cells expressing both mesenchymal and hematopoi-
etic markers have been identified at sites of pathological
fibroses and have been named fibrocytes. Fibrocytes
have mixed features of both hematopoietic and mesen-
chymal cells, because they express both cell surface
antigens of the hematopoietic lineage, such as CD45 and
CD11b, and matrix proteins, particularly type 1 colla-
gen,16 and they derive from BM precursors. They con-
tribute to wound healing27 and to pathological fibrosis28
by secreting matrix and pro-angiogenic factors, and by
GFP
P=0.09
WT  
WT/GFP
   PBS  
WT/GFP
   PTH  
PBS PTH
A
B
Figure 5. Identification and characterization of GFPCD45 cells in
Col2.3GFP mice after PTH treatment. An endosteal cell fraction (fraction 2)
was isolated from Col2.3/GFP (treated and untreated) mice. Cells were
stained with anti-CD45 antibody and analyzed by flow cytometry. A: Repre-
sentative samples of each group. B: The percentage of GFP CD45 cells in
vehicle- versus PTH- treated samples (n  3). P  0.09.differentiating into myofibroblasts.29 Another cell popula-tion, called circulating osteoprogenitor cells, which also
expresses CD45 and type 1 collagen, has differentiated
into osteoblasts and potentially plays a critical role in the
pathogenesis of fibrodysplasia ossificans progressiva.30
According to the notion that the minimum criteria of
co-expression of collagen and hematological markers
are sufficient to define fibrocytes as such, our findings
indicate that the novel cells we have identified in the BM
are fibrocyte-like. It is intriguing that these BM fibrocyte-
like cells are expanded in PPR*Tg mice, which is a model
of marrow fibrosis. PTH treatment increased the number
of GFPCD45 cells in the endosteal fraction but not in
the rest of the BM. This finding is particularly interesting
considering that marrow fibrosis is observed mainly in the
endosteal region in PTH-treated rodents (data not
shown).31 Notably, as previously reported and consistent
with the constitutive activity of the transgene, serum PTH
levels are partially suppressed in PPR*Tg mice.12
The presence of fibrocytes in the BM has not been
previously reported in a direct fashion, although it is no-
table that similar cells have been reported to be present
in the BM. In these studies, single enhanced green fluo-
rescence protein plus HSCs were transplanted into mice,
and fibroblast-like cells expressing enhanced green flu-
orescence protein and type 1 collagen were observed
either in BM culture studies17 or in vivo, contributing to
tumor stroma.18 Our studies expand on these findings,
demonstrating in three different mouse models (WT,
PPR*Tg, andGFPmouse strains) that lineage-negative cells
that express CD45, CD11b, and type 1 collagen are present
in the BM in homeostasis conditions, and are elevated in a
mouse model of fibrosis. Furthermore, these fibrocyte-like
cells can be further subdivided by their expression of the
macrophage marker, F4/80, and most of these cells do not
express the HSCmarkers, ScaI and c-Kit, although they are
progeny of transplantable BM cells (data not shown), in
agreement with the findings of Ebihara et al.17
Interestingly, in previous studies, Ebihara et al17 found
that GFP-positive colony-forming cells differentiated into
Col1CD45 cells or Mac1 macrophage-like cells, de-
pending on culture conditions. Our studies suggest that
the Col1CD45CD11b population contains a subpopu-
lation with characteristics of fibroblasts (F4/80 cells) and a
subpopulation with characteristics of macrophages (F4/80
cells). Our current working hypothesis is that the BM, like
wounds and pathological fibroses, is a permissive microen-
vironment for the differentiation of fibrocyte-like cells from
hematopoietic precursors, and that these cells may contrib-
ute to the marrow fibrosis and/or BM homeostasis with yet
unknown mechanisms. It is also possible that these fibro-
cyte-like cells share the same precursor as macrophages.
To this end, further investigation of the F480 and F4/80
subpopulations of the Col1CD45CD11b BM cells will
expand our understanding of these fibrocyte-like cells,
which is of clinical importance.
Different from transgenic mice, in which GFP is driven
by the 3.6-kb fragment of the a1(I) collagen gene pro-
moter,20 TRAP-positive multinucleated osteoclasts did
not express GFP in our model. However, to this end, we
cannot fully exclude the possibility that GFPCD45cells, which also express RANK, differentiate into oste-
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hence, GFP) in their differentiation process.
We have previously reported that the marrow fibrosis
observed in PPR*Tg mice, as in hyperparathyroidism and
fibrous dysplasia in humans, is mainly contributed by
cells of the osteoblast lineage at early stages of differen-
tiation.12 The present study has confirmed these obser-
vations by showing by both a genetic approach and by in
situ hybridization analysis that marrow fibrosis in PPR*Tg
mice is formed by type I collagen–producing cells, but it
is not contributed by terminally differentiated osteoblasts.
No expansion of immature cells expressing ScaI was
observed in PPR*Tg mice. This finding is consistent with
the finding that MSCs/progenitors, defined as cells gen-
erating colony-forming unit fibroblastoid in vitro, decline
with age in PPR*Tg mice.32 Interestingly, intermittent PTH
administration has expanded the pool of MSCs/progeni-
tors expressing nestin.25 The apparent discrepancies
with our findings could be the result of the fact that ScaI
defines a population distinct from nestin-expressing cells
or that intermittent PTH treatment has different effects on
MSCs/progenitors when compared with long-term activa-
tion of PPR as it occurs in PPR*Tg mice. Further studies
are required to address this important issue.
In summary, we have identified a novel population of
cells expressing both hematopoietic and mesenchymal
markers in the normal adult BM, which is significantly
augmented in a murine model of marrow fibrosis. The
clinical relevance of our findings in pathological settings,
such as primary and secondary hyperparathyroidism and
fibrous dysplasia, requires further studies.
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